# BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct07108309/  
OnCo record `nct07108309` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of BCD-236 in triple-negative breast cancer, run by Biocad, now recruiting.

## Summary

BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer is a phase 2 interventional study registered as NCT07108309 by Biocad, with 124 participants planned, started 2024-07-15 and due to reach its primary completion in 2025-12. Interventions recorded: BCD-236 and Chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07108309
- Phase: 2
- Setting: A Randomized, Open-label, Comparative Clinical Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
- Sponsor: Biocad
- Enrolled: 124

## Sources

- ClinicalTrials.gov NCT07108309: https://clinicaltrials.gov/study/NCT07108309

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- companies: [Biocad](https://onco.cc/companies/biocad/)

---
JSON: https://onco.cc/api/v1/entities/nct07108309.json